Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Company price
0.75 USD -0.06 ( 7.35%)
Last update at 2026-11-16T14:30:00Z
VOLUME
400
Market Cap
0.16M

Momentum Score

…

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.75
Low
0.75
High
52 Week Price Range
0.00
Low
0.45
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Public filings and company disclosures for Greater Cannabis Company Inc (PINK: GCAN) are limited, offering little verifiable operational or financial detail. Listed as a cannabis-sector issuer, it may benefit from long-term growth in legalized markets and potential industry consolidation if management develops operations and improves transparency.

Key risks include minimal public disclosure, OTC Pink listing with low liquidity, regulatory uncertainty for cannabis businesses, and execution and financing risk common to small, underreported issuers.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.81
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-0.00M
Debt / Equity
-0.36
ROE
-
Net Debt
0.26M
ROCE
44.49%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -0.33M -0.18M -0.19M -0.36M -0.60M
Net income -0.33M -0.18M -0.19M -0.54M -0.51M
Selling general administrative 0.12M 0.12M 0.12M 0.12M 0.15M
Gross profit -0.00M 0.00M -0.01M -0.05M -0.00M
Reconciled depreciation 0.00M 0.01M 0.01M 0.01M 0.01M
Ebit -0.33M -0.16M -0.18M -0.18M -0.34M
Ebitda -0.33M -0.15M -0.17M -0.23M -0.72M
Depreciation and amortization 0.00M 0.01M 0.01M -0.06M -0.37M
Operating income -0.18M -0.16M -0.18M -0.18M -0.34M
Other operating expenses 0.18M - 0.18M 0.18M 0.36M
Interest expense 0.00M 0.02M 0.01M 0.12M 0.29M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income -0.00M -0.02M -0.02M -0.12M -0.29M
Income tax expense - - - 0.18M -0.09M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.01M
Total operating expenses 0.18M 0.16M 0.17M 0.18M 0.34M
Cost of revenue 0.00M 0.00M 0.01M 0.05M 0.01M
Total other income expense net -0.15M -0.02M -0.01M -0.18M -0.26M
Net income from continuing ops -0.33M -0.18M -0.19M -0.36M -0.60M
Net income applicable to common shares - - - - -0.60M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 0.00M 0.06M 0.17M 0.28M 0.39M
Intangible assets - 0.00M 0.01M 0.01M 0.02M
Total liab 0.74M 0.90M 0.83M 0.83M 0.86M
Total stockholder equity -0.74M -0.84M -0.66M -0.54M -0.47M
Other current liab 0.47M 0.46M 0.40M 0.31M 0.22M
Common stock 1.35M 0.80M 0.80M 0.73M 0.51M
Capital stock 1.36M 0.81M 0.81M 0.74M 0.52M
Retained earnings -4.99M -4.66M -4.48M -4.29M -3.93M
Cash 0.00M 0.06M 0.17M 0.27M 0.38M
Total current liabilities 0.74M 0.90M 0.83M 0.83M 0.86M
Net debt 0.26M 0.37M 0.26M 0.23M 0.25M
Short term debt 0.26M 0.43M 0.43M 0.50M 0.63M
Short long term debt 0.26M 0.43M 0.43M 0.50M 0.63M
Short long term debt total 0.26M 0.43M 0.43M 0.50M 0.63M
Other stockholder equity 2.89M 3.01M 3.81M 3.01M 2.95M
Total current assets 0.00M 0.06M 0.17M 0.27M 0.38M
Net tangible assets - - - - -0.49M
Accounts payable 0.01M 0.01M 0.01M 0.02M 0.01M
Accumulated other comprehensive income - - -0.80M - -
Non currrent assets other - 0.00M 0.00M - -
Non current assets total 0.00M 0.00M 0.01M 0.01M 0.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M 0.00M 0.00M 0.00M
Change to liabilities - - - - 0.00M
Net borrowings 0.00M 0.00M 0.00M - 0.50M
Total cash from financing activities 0.00M 0.00M 0.00M 0.00M 0.50M
Change to operating activities - - - - 0.12M
Net income -0.33M -0.18M -0.19M -0.36M -0.60M
Change in cash -0.06M -0.11M -0.10M -0.11M 0.26M
Begin period cash flow 0.06M 0.17M 0.27M 0.38M 0.11M
End period cash flow 0.00M 0.06M 0.17M 0.27M 0.38M
Total cash from operating activities -0.06M -0.11M -0.10M -0.11M -0.24M
Depreciation 0.00M 0.01M 0.01M 0.01M 0.01M
Other cashflows from financing activities 0.00M - - - 0.50M
Change to netincome - - - - -0.03M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.09M 0.06M 0.08M 0.09M 0.12M
Stock based compensation 0.00M 0.04M 0.08M - -
Other non cash items 0.18M 0.06M -0.08M 0.16M 0.24M
Free cash flow -0.06M -0.11M -0.10M -0.11M -0.24M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GCAN
Greater Cannabis Company Inc
-0.06
7.35%
0.75 - - 39.37 - 71.46 -2.33
MKKGY
Merck KGaA ADR
0.40
1.22%
33.13 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien
-
-%
169.65 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR
-
-%
21.64 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.
-
-%
43.15 - 10.66 0.01 1.16 2.94 23.11

Profile*

Greater Cannabis Company Inc

The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd. that focuses on treatment of autism, schizophrenia, Parkinson's disease, Alzheimer's disease, and other neuropsychiatric disorders. The company was founded in 2014 and is based in Baltimore, Maryland.

2833 Smith Avenue, Baltimore, MD, United States, 21209

443 738 4051

1

Name Title Year Born
Mr. Aitan Zacharin Chairman, Pres, CEO, Acting CFO & Treasurer 1983
Mr. Aitan Zacharin Chairman, President, CEO, Acting CFO & Treasurer 1983
Motti Stenge Chief Operating Officer NA
Dr. Adi Aran M.D. Chief Scientific Advisor NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…